Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide.

Villano M, Borghini A, Manetti M, Gabbrielli E, Rossi A, Sestini P, Milia A, Nacci F, Guiducci S, Matucci-Cerinic M, Ibba-Manneschi L, Weber E.

Arthritis Res Ther. 2013 Aug 20;15(4):R90. doi: 10.1186/ar4270.

2.

Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen.

Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, Korn JH, Lafyatis R.

Arthritis Rheum. 2004 Mar;50(3):915-26.

3.

Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide.

Borghini A, Manetti M, Nacci F, Bellando-Randone S, Guiducci S, Matucci-Cerinic M, Ibba-Manneschi L, Weber E.

PLoS One. 2015 Jun 15;10(6):e0130166. doi: 10.1371/journal.pone.0130166. eCollection 2015.

4.

Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma).

Wallis DD, Tan FK, Kielty CM, Kimball MD, Arnett FC, Milewicz DM.

Arthritis Rheum. 2001 Aug;44(8):1855-64.

5.
6.

Human microvascular lymphatic and blood endothelial cells produce fibrillin: deposition patterns and quantitative analysis.

Rossi A, Gabbrielli E, Villano M, Messina M, Ferrara F, Weber E.

J Anat. 2010 Dec;217(6):705-14. doi: 10.1111/j.1469-7580.2010.01306.x. Epub 2010 Oct 11.

7.
8.

Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis.

Wipff J, Avouac J, Le Charpentier M, Varret M, Houtteman A, Ruiz B, Vacher-Lavenu MC, Kahan A, Boileau C, Allanore Y.

Rheumatology (Oxford). 2010 Apr;49(4):657-61. doi: 10.1093/rheumatology/kep433. Epub 2010 Jan 16.

PMID:
20081226
9.
10.
11.

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis.

Mazzotta C, Romano E, Bruni C, Manetti M, Lepri G, Bellando-Randone S, Blagojevic J, Ibba-Manneschi L, Matucci-Cerinic M, Guiducci S.

Arthritis Res Ther. 2015 Aug 21;17:221. doi: 10.1186/s13075-015-0749-4.

12.

Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation.

Kissin EY, Lemaire R, Korn JH, Lafyatis R.

Arthritis Rheum. 2002 Nov;46(11):3000-9.

13.

Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta.

Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Baldwin AK, McGovern A, Baldock C, Shuttleworth CA, Kielty CM.

J Cell Sci. 2010 Sep 1;123(Pt 17):3006-18. doi: 10.1242/jcs.073437. Epub 2010 Aug 10.

14.

Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma.

Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, Dietz HC.

Nature. 2013 Nov 7;503(7474):126-30. doi: 10.1038/nature12614. Epub 2013 Oct 9.

15.

Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study.

Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, Guiducci S.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S148-52. Epub 2015 Jun 19.

PMID:
26088817
16.

Differential expression of junctional adhesion molecules in different stages of systemic sclerosis.

Manetti M, Guiducci S, Romano E, Rosa I, Ceccarelli C, Mello T, Milia AF, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M.

Arthritis Rheum. 2013 Jan;65(1):247-57. doi: 10.1002/art.37712.

18.

MAGP-2 has multiple binding regions on fibrillins and has covalent periodic association with fibrillin-containing microfibrils.

Hanssen E, Hew FH, Moore E, Gibson MA.

J Biol Chem. 2004 Jul 9;279(28):29185-94. Epub 2004 May 6.

19.

Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis.

Romano E, Chora I, Manetti M, Mazzotta C, Rosa I, Bellando-Randone S, Blagojevic J, Soares R, Avouac J, Allanore Y, Ibba-Manneschi L, Matucci-Cerinic M, Guiducci S.

Ann Rheum Dis. 2016 Aug;75(8):1541-9. doi: 10.1136/annrheumdis-2015-207483. Epub 2015 Sep 10.

PMID:
26359450
20.

Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.

Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M.

Circ Res. 2011 Jul 22;109(3):e14-26. doi: 10.1161/CIRCRESAHA.111.242057. Epub 2011 Jun 2.

Supplemental Content

Support Center